TerminatedPHASE2, PHASE3NCT04817761
SPARK-ALL: Calaspargase Pegol in Adults With ALL
Studying Adult T-cell leukemia/lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Institut de Recherches Internationales Servier
- Principal Investigator
- Daniel J. DeAngelo, MD, PhDDana-Farber Cancer Institute, Boston, MA
- Intervention
- Calaspargase pegol (S95015)(drug)
- Enrollment
- 42 enrolled
- Eligibility
- 22-55 years · All sexes
- Timeline
- 2021 – 2025
Study locations (21)
- HonorHealth Cancer Transplant Institute, Scottsdale, Arizona, United States
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- Univeristy of California, Los Angeles, California, United States
- University of California Irvine Health (UCI Health), Orange, California, United States
- University of Miami Health System - Sylvester Comprehensive Cancer Center, Miami, Florida, United States
- University of Chicago Medicine, Chicago, Illinois, United States
- University of Kansas Cancer Center - Richard and Annette Bloch Cancer Care Pavilion, Westwood, Kansas, United States
- University of Maryland Greenbaum Cancer Center, Baltimore, Maryland, United States
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
- Dana Farber Cancer Institute, Weymouth, Massachusetts, United States
- Northwell Health Cancer Institute, Lake Success, New York, United States
- NYU Langone/Laura and Isaac Perlmutter Cancer Center, New York, New York, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Duke University, Durham, North Carolina, United States
- Cleveland Clinic, Cleveland, Ohio, United States
- +6 more locations on ClinicalTrials.gov
Collaborators
ADIR, a Servier Group company
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04817761 on ClinicalTrials.govOther trials for Adult T-cell leukemia/lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07388563Azacitidine and Abatacept in Relapsed or Refractory T-Cell LymphomaNational Cancer Institute (NCI)
- RECRUITINGPHASE1, PHASE2NCT05745714HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesPrincess Maxima Center for Pediatric Oncology
- RECRUITINGPHASE2NCT07159620Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like PatientsThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE1NCT07108868A Phase I Dose Finding Study of MB-CART2219.1University Hospital Tuebingen
- RECRUITINGNCT05237986Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell TherapyNational Cancer Institute (NCI)
- RECRUITINGPHASE1, PHASE2NCT07008885BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALLChinese PLA General Hospital
- ACTIVE NOT RECRUITINGPHASE3NCT07541755PD-1 Inhibitors +Venetoclax+CAG Regimens in R/R T-ALLFujian Medical University Union Hospital
- RECRUITINGPHASE2NCT06698003A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1Memorial Sloan Kettering Cancer Center